产品简要
公司名称 :
Novus Biologicals
其他品牌 :
IMGENEX
产品类型 :
抗体
产品名称 :
小鼠单克隆血管内皮生长因子抗体
目录 :
NB100-664
规格 :
0.1 mg (also 0.025 mg)
价格 :
349美元
克隆性 :
单克隆
宿主 :
小鼠
共轭标签 :
nonconjugated
克隆名称 :
VG1
反应物种 :
人类, 小鼠, 大鼠,
应用 :
免疫印迹, 酶联免疫吸附测定, 免疫组化, 免疫细胞化学, 流式细胞仪, 免疫组化-石蜡切片, 免疫组化-冰冻切片
更多信息或购买 :
文章摘录数: 24
出版应用/物种/样品/稀释参考文献
  • 免疫印迹; 小鼠
Shao J, Zhang Y, Yang T, Qi J, Zhang L, Deng L. HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression. In Vitro Cell Dev Biol Anim. 2015;51:808-14 pubmed 出版商
  • 免疫组化-冰冻切片; 大鼠
Tam J, Ko C, Lau K, To M, Kwok H, Chan Y, et al. A Chinese 2-herb formula (NF3) promotes hindlimb ischemia-induced neovascularization and wound healing of diabetic rats. J Diabetes Complications. 2014;28:436-47 pubmed 出版商
  • 免疫印迹; 大鼠
Fedorova L, Sodhi K, Gatto Weis C, Puri N, Hinds T, Shapiro J, et al. Peroxisome proliferator-activated receptor ? agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE. 2013;8:e64436 pubmed 出版商
  • 免疫细胞化学; 小鼠
  • 免疫组化; 小鼠
Milanesi A, Lee J, Li Z, DA Sacco S, Villani V, Cervantes V, et al. ?-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PLoS ONE. 2012;7:e42177 pubmed 出版商
  • 免疫组化-石蜡切片; 小鼠
Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol. 2008;32:1049-56 pubmed
  • 免疫印迹; 人类
Ptaszynska M, Pendrak M, Bandle R, Stracke M, Roberts D. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res. 2008;6:352-63 pubmed 出版商
  • 免疫组化-石蜡切片; 人类
  • 免疫印迹; 人类
O Byrne K, Koukourakis M, Giatromanolaki A, Cox G, Turley H, Steward W, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000;82:1427-32 pubmed
  • 免疫组化-石蜡切片; 人类
  • 酶联免疫吸附测定; 人类
  • 免疫印迹; 人类
Turley H, Scott P, Watts V, Bicknell R, Harris A, Gatter K. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol. 1998;186:313-8 pubmed
  • 免疫组化; 人类
Giatromanolaki A, Koukourakis M, Kakolyris S, Turley H, O Byrne K, Scott P, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4:3017-24 pubmed
Parlakgumus H, Aka Bolat F, Bulgan Kilicdag E, Simsek E, Parlakgumus A. Atorvastatin for ovarian torsion: effects on follicle counts, AMH, and VEGF expression. Eur J Obstet Gynecol Reprod Biol. 2014;175:186-90 pubmed 出版商
Johansen F, Hasseldam H, Rasmussen R, Bisgaard A, Bonfils P, Poulsen S, et al. Drug-induced hypothermia as beneficial treatment before and after cerebral ischemia. Pathobiology. 2014;81:42-52 pubmed 出版商
Hong D, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011;17:6582-91 pubmed 出版商
Van der Auwera I, Van Laere S, Van den Eynden G, Benoy I, Van Dam P, Colpaert C, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965-71 pubmed
Couvelard A, O Toole D, Turley H, Leek R, Sauvanet A, Degott C, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92:94-101 pubmed
Giatromanolaki A, Koukourakis M, Simopoulos C, Polychronidis A, Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol. 2003;29:879-83 pubmed
Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18:418-22 pubmed
Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, Wykoff C, Gatter K, et al. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003;200:222-8 pubmed
Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter K, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209-13 pubmed
Salgado R, Benoy I, Weytjens R, Van Bockstaele D, Van Marck E, Huget P, et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer. 2002;87:1437-44 pubmed
Zhang H, Scott P, Morbidelli L, Peak S, Moore J, Turley H, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer. 2000;83:63-8 pubmed
Koukourakis M, Giatromanolaki A, Thorpe P, Brekken R, Sivridis E, Kakolyris S, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000;60:3088-95 pubmed
Adams J, Carder P, Downey S, Forbes M, MacLennan K, Allgar V, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60:2898-905 pubmed
Giatromanolaki A, Koukourakis M, Sivridis E, O Byrne K, Cox G, Thorpe P, et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res. 2000;6:1917-21 pubmed
Kakolyris S, Giatromanolaki A, Koukourakis M, Leigh I, Georgoulias V, Kanavaros P, et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res. 1999;59:5602-7 pubmed
产品信息
SKU号 :
NB100-664
产品名称 :
小鼠单克隆血管内皮生长因子抗体
规格 :
0.1 mg (also 0.025 mg)
描述 :
The VEGF Antibody (VG1) from Novus Biologicals is a mouse monoclonal antibody to VEGF. This antibody reacts with human, mouse, rat, canine. The VEGF Antibody (VG1) has been validated for the following applications: Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, CyTOF-ready.
靶标 :
血管内皮生长因子
类别 :
一抗
缓冲液 :
小鼠单克隆血管内皮生长因子抗体用品在PBS
克隆性 :
单克隆
克隆 :
VG1
浓度 :
1毫克/毫升
共轭标签 :
未共轭
宿主 :
小鼠
免疫原 :
重组血管内皮生长因子189蛋白
抗体亚型 :
IgG1 Kappa
纯度 :
蛋白质G纯化
物种活性 :
人类, 小鼠, 大鼠, 狗
特异性 :
This VEGF Antibody (VG1) detects the 189, 165 and 121 isoforms of VEGF
基因符号 :
血管内皮生长因子A
AccessionNumbers :
P15692
应用 :
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, CyTOF-ready
价格 :
349美元
又名 :
MVCD1, 血管内皮生长因子, 血管通透性因子, 血管内皮生长因子-A, VEGFMGC70609, VPFvascular血管内皮生长因子
储存 :
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
更多信息或购买 :
公司信息
Novus Biologicals
8100 Southpark Way, A-8
Littleton, CO 80120
technical@novusbio.com
https://www.novusbio.com
1-888-506-6887 303-730-1950
公司总部: 美国
Novus Biologicals的任务是开发最先进的新产品及市场行销来加速生物科研的新发现。藉由高效率的组织分工,Novus Biologicals建立了一个将生物学术团体的成果快速商品化的平台。我们的产品除了附有详细的产品资讯外,Novus Biologicals更提供完整的技术支援及服务。利用快速有效的市场通路以便迅速提供所有的科研学者最先进的研究试剂,Novus Biologicals扮演市场上重要的角色。